"Today's drug and chemical safety assessment process increasingly leverages information from many different sources," said Dr. Richard Brennan, GeneGo's Director of Toxicology. "Molecular toxicologists need to be able to put traditional toxicology measurements in the context of chemical information as well as biochemical, gene expression, protein and metabolite data. Industry needs scientists well-versed in complex systems biology data, and in the powerful and flexible analysis tools increasingly used in safety assessment. UC Berkeley is leading the way in providing training in current and emerging technologies, and we are pleased to be able to contribute to this cutting-edge program."
GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.5(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.5(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com
MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM) and MetaMiner(TM), 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.
|SOURCE GeneGo, Inc.|
Copyright©2008 PR Newswire.
All rights reserved